Luca Porcu
Mario Negri Institute for Pharmacological Research
CancerSurgeryOncologyRetrospective cohort studyHazard ratioMetastatic breast cancerLung cancerChemotherapyRenal cell carcinomaEpilepsyDiseaseTrastuzumabVinorelbineTrabectedinCancer researchColorectal cancerBreast cancerClinical trialMedicineBiomarker (medicine)
111Publications
16H-index
970Citations
Publications 113
Newest
#1Silvia NovelloH-Index: 61
#2Valentina MonicaH-Index: 16
Last. G. V. ScagliottiH-Index: 23
view all 35 authors...
Source
#1Serena Di CosimoH-Index: 28
#2Luca PorcuH-Index: 16
Last. Fatima Cardoso (Champalimaud Foundation)H-Index: 60
view all 3 authors...
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic management of HR+/HER2-advanced breast cancer by prolonging progression-free and overall survival when given in combination with endocrine therapy. In this article, available data from PALLAS and mona...
Source
#1Simonetta Genovesi (University of Milan)H-Index: 2
#2Luca PorcuH-Index: 16
Last. Patrizio Mazzone (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 27 authors...
BACKGROUND In patients with end stage renal disease and atrial fibrillation (AF), undergoing chronic dialysis, direct oral agents are contraindicated and warfarin does not fully prevent embolic events while increasing the bleeding risk. The high hemorrhagic risk represents the main problem in this population. Aim of the study was to estimate the safety and efficacy for thromboembolic prevention of left atrial appendage (LAA) occlusion in a cohort of dialysis patients with AF and high hemorrhagic...
3 CitationsSource
#1Simonetta Genovesi (University of Milan)H-Index: 17
#2Luca PorcuH-Index: 16
Last. Patrizio Mazzone (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 27 authors...
Source
#1Anna NigriH-Index: 10
#2Lidia SarroH-Index: 12
Last. Lorenzo NanettiH-Index: 16
view all 13 authors...
Source
#1Nicla La VerdeH-Index: 15
#2Elena CollovàH-Index: 9
Last. Sandro BarniH-Index: 55
view all 18 authors...
Source
#1Serena Di CosimoH-Index: 28
#2Luca PorcuH-Index: 16
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 13 authors...
Source
#1Michele ReniH-Index: 53
#2Francesca BergamoH-Index: 23
Last. Giordano D. BerettaH-Index: 21
view all 20 authors...
Source
#1S.K. Garattini (University of Udine)H-Index: 3
#2Marta BonottoH-Index: 15
Last. Nicoletta PellaH-Index: 15
view all 17 authors...
Background: 'Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials & methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previou...
Source
#1Stefano RadaelliH-Index: 17
#2Piero FossatiH-Index: 18
Last. Alessandro GronchiH-Index: 70
view all 68 authors...
Abstract Objective Aim of the manuscript is to discuss how to improve margins in sacral chordoma. Background Chordoma is a rare neoplasm, arising in half cases from the sacrum, with reported local failure in >50% after surgery. Methods A multidisciplinary meeting of the “Chordoma Global Consensus Group” was held in Milan in 2017, focusing on challenges in defining and achieving optimal margins in chordoma with respect to surgery, definitive particle radiation therapy (RT) and medical therapies. ...
1 CitationsSource
12345678910
Close Researchers